Immunome appoints Bob Lechleider, M.D., as CMO

Immunome announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research. “We are delighted to welcome Bob to our team during an exciting time in Immunome’s growth as we focus on advancing our oncology pipeline into the clinic,” said Dr. Siegall, President and Chief Executive Officer of Immunome. “Bob’s extensive experience in both early and late-stage oncology programs, including the successful initial licensing of Padcev , an antibody-drug conjugate for the treatment of urothelial cancer, is expected to add significant value to Immunome’s vision of developing first-in-class and best-in-class targeted cancer therapies for patients.”